Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-01-04
2005-01-04
Priebe, Scott D. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000, C424S093200
Reexamination Certificate
active
06838446
ABSTRACT:
This invention relates particularly to gene directed enzyme prodrug therapy (GDEPT) using post translational glycosylphosphatidylinositol (GPI addition to a prodrug activating enzyme to enable anchorage of the enzyme at the cell surface, particularly for use in cancer therapy. A preferred prodrug activating enzyme is carboxypeptidase G2.
REFERENCES:
patent: 5109113 (1992-04-01), Caras et al.
patent: 5264357 (1993-11-01), Caras et al.
patent: 5374548 (1994-12-01), Caras
patent: 5418147 (1995-05-01), Huang et al.
patent: 0244267 (1987-11-01), None
patent: WO 8901041 (1989-02-01), None
patent: WO 9401463 (1994-01-01), None
patent: WO 9603515 (1996-02-01), None
patent: WO 9719180 (1997-05-01), None
patent: WO 9851787 (1998-11-01), None
Ali et al., “A protein targeting signal that functions in polarized epithelial cells in vivo”, Biochem., 1996, vol. 315, pp. 857-862.
Anthony et al., “The Biological Chemistry of Folate Receptors”, Blood, The Journal of The American Society of Hematology, Jun., 1992, pp. 2807-2820.
Clissold, “A cDNA construct of tissue inhibitor of metalloproteinases (TIMP) linked to the last exon of Thy-1 confers glycophospholipid anchorage on this naturally secreted protein”, Biochem. J., 1992, vol. 281, pp. 129-136.
Clissold et al., “Construction, expression and functional analysis of glycolipid-linked form of CRI”, Eur J Immunol, vol. 23, 1993, pp. 2346-2352.
Clissold, “Recombinant glycosyl-phosphatidylinositol-anchored proteins are not associated with protein kinases in trasfected thymoma cells”, Biochem. J., 1994, vol. 304, pp. 853-859.
Douglas et al., “Targeted gene delivery by tropism-modified adenoviral vectors”, Nature Biotechnology, Nov. 1996, vol. 14, pp. 1574-1578.
Douglas et al., “Targeted Gene Therapy”, Tumor Targeting, 1995, vol. 1, pp. 67-84.
Harrison et al., “A convenient method for the construction and expression of GPI-anchored proteins”, Nucleic Acid Research, 1994, vol. 22, No. 18, pp. 3813-3814.
Hooper, “Glycosyl-phosphatidylinositol anchored membrane enzymes”, Clinica Chimica Acta, 1997, vol. 266, pp. 3-12.
Hooper et al., “Identification of membrane dipeptidase as a major glycosyl-phosphatidylinositol-anchored protein of the pancreatic zymogen granule membrane, and evidence for its release by phospholipase A”, Biochem. J. 1997, vol. 324, pp. 151-157.
Kennard et al., GPI-Anchored Fusion Proteins, Methods of Biotechnology, vol. 8, Animal Cell Biotechnology, 1999, pp. 187-199.
Kinoshita et al., “GPI-Anchor Synthesis in Mammalian Cells: Genes, Their Products, and a Deficiency”, J. Biochem., 1997, vol. 122, pp. 251-257.
Lisanti et al., “Fusion proteins containing a minimal GPI-attachment signal are apically expressed in trasfected MDCK cells”, Journal of Cell Science, 1991, vol. 99, pp. 637-640.
Lowenstein et al., “Simultaneous detection of amplicon and HSV-1 helper encoded proteins reveals that neurons and astrocytoma cells do express amplicon-borne transgenes in the absence of synthesis of virus immediate early proteins”, Molecular Brain Research, 1995, vol. 30, pp. 169-175.
Moran et al., “Proteins Containing an Uncleaved Signal for Glycophosphatidylinositol Membrane Anchor Attachment are Retained in a Post-ER Compartment”, Journal of Cell Biology, Nov. 1992, vol. 119, No. 4, pp. 763-772.
Robbins et al., “Viral Vectors for Gene Therapy”, Pharmacol. Ther., 1998, vol. 80, No. 1, pp. 35-47.
Soole et al., “A glycosyl-phosphatidylinositol anchor can target a bacterial enzyme to the apical surface of polarized epithelial cells”, Biochemical Society Transactions, 1992, p. 21.
ten Dam et al., “Cell surface GPI-anchoring of CD45 isoforms”, Molecular Biology Reports, 1998, vol. 25, pp. 197-204.
Udenfriend et al., “How Glycosylphosphatidylinositol-Anchored Membrane Proteins are Made”, Annu. Rev. Biochem, 1995, vol. 64, pp. 563-591.
Verkman et al., “Endosomes from kidney collecting tubule cells cotnain the vasopressin-sensitive water channel”, Nature, May 1988, vol. 333, pp. 268-272.
Hamstra, D.A. et al.: “Expression of Endogenously Activated Secreted or Cell Surface Carboxypeptidase A Sensitizes Tumor Cells to Methotrexate-alpha-Peptide Prodrugs” Cancer Research, vol. 60, No. 3, Feb. 1, 2000, pp. 657-665, XP000926076 the whole document.
Seki, T. et al.: “The human Thy-1 gene: Structure and chromosomal location” Proceedings of the National Academy of Sciences of USA, vol. 82, No. 19 Oct. 1985, pp. 6657-6661, XP000926079, the whole document.
Marais, R. et al. : “A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy” Nature Biotechnology, vol. 15, No. 13, Dec. 1997, pp. 1373-1377, XP002079969 cited in the application, the whole document.
AstraZeneca AB
Morgan & Lewis & Bockius, LLP
Priebe Scott D.
LandOfFree
Vector for expression of GPI-enzyme hybrid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vector for expression of GPI-enzyme hybrid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vector for expression of GPI-enzyme hybrid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3376219